Investigational drug · Phase 2
KP104
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glomerulonephritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "KP104"
First trial start
2025
Dec 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KP104", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glomerulonephritis
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "KP104" as an intervention, largest first.
Kira Pharmacenticals (US), LLC.Industry
NCT05490017 · 80 participants · Start Dec 30, 2020 · Primary completion May 4, 2022
Drug: KP104; Placebo · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Adelaide, Australia
- Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat GlomerulonephritisRecruiting
Kira Pharmacenticals (US), LLC.Industry
NCT05517980 · 52 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 2028
Drug: KP104 · For: Glomerulonephritis
Sites: Beijing, China
- To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104Status unknown
Kira Pharmacenticals (US), LLC.Industry
NCT05476887 · 35 participants · Start Nov 25, 2022 · Primary completion Nov 2024
Drug: KP104 · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Beijing, China; Nanjing, China; Tianjin, China · 4 sites in all
Kira Pharmacenticals (US), LLC.Industry
NCT05504187 · 0 participants · Start Mar 2025 · Primary completion Mar 2026
Drug: KP104 · For: Systemic Lupus Erythematosus
Newest research
PubMed records naming it or its code names, newest first.
- Characterisation of plasmids encoding CTX-M-3 extended-spectrum beta-lactamase from Enterobacteriaceae isolated at a university hospital in Taiwan.
Liu SY, Su LH, Yeh YL, et al. · Int J Antimicrob Agents 2007
- [Membrane biophysical interaction of amlodipine and antioxidant properties].
Mason RP, Trumbore MW, Mason PE · Drugs 2000
Also in development for Glomerulonephritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.